Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119


Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. Epub 2006 Nov 6.


Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.

Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.

Clin Cancer Res. 2006 Mar 1;12(5):1593-8.


Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.

Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT.

Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42. Review.


Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.

Clin Cancer Res. 1999 Nov;5(11):3488-99.


Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.

Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT.

Clin Cancer Res. 2002 Aug;8(8):2640-6.


AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.

Pépin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4418-27. doi: 10.1073/pnas.1510604112. Epub 2015 Jul 27.


Identification of a receptor for human müllerian inhibiting substance.

Catlin EA, Ezzell RM, Donahoe PK, Gustafson ML, Son EV, MacLaughlin DT.

Endocrinology. 1993 Dec;133(6):3007-13.


Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK.

Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6. Epub 2004 Dec 23. Erratum in: Proc Natl Acad Sci U S A. 2005 May 3;102(18):6513.


Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.

Donahoe PK, Fuller AF Jr, Scully RE, Guy SR, Budzik GP.

Ann Surg. 1981 Oct;194(4):472-80.


Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Chang HL, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin DT, Donahoe PK.

Gynecol Oncol. 2011 Jan;120(1):128-34. doi: 10.1016/j.ygyno.2010.09.017. Epub 2010 Nov 6.


Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.

Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S.

J Biol Chem. 2000 Nov 24;275(47):37101-9.


Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.

Fuller AF Jr, Krane IM, Budzik GP, Donahoe PK.

Gynecol Oncol. 1985 Oct;22(2):135-48.


The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.

Song JY, Chen KY, Kim SY, Kim MR, Ryu KS, Cha JH, Kang CS, MacLaughlin DT, Kim JH.

Int J Oncol. 2009 Jun;34(6):1583-91.


Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.

Catlin EA, Uitvlugt ND, Donahoe PK, Powell DM, Hayashi M, MacLaughlin DT.

Metabolism. 1991 Nov;40(11):1178-84.


Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.

Chin TW, Parry RL, Donahoe PK.

Cancer Res. 1991 Apr 15;51(8):2101-6.


Localization of Mullerian inhibiting substance receptors in various human cancer cell lines.

Rodina AV, Gukasova NV, Makarov VA, Kondrasheva IG, Khomyakova AV, Posypanova GA, Popova ON, Moskaleva EY, Severin SE.

Biochemistry (Mosc). 2008 Jul;73(7):797-805.


The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.

Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA.

Mol Endocrinol. 2001 Jun;15(6):936-45.


c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.

Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J.

Endocrinology. 2008 Jan;149(1):108-15. Epub 2007 Oct 18.


Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9. Epub 2006 Jul 18.


Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines.

Jung YS, Kim HJ, Seo SK, Choi YS, Nam EJ, Kim S, Kim SW, Han HD, Kim JW, Kim YT.

Yonsei Med J. 2016 Jan;57(1):33-40. doi: 10.3349/ymj.2016.57.1.33.

Supplemental Content

Support Center